ConductScience.org, home

Paper7842289

Induction of lymphokine-activated killing with reduced secretion of interleukin-1 beta, tumor necrosis factor-alpha, and interferon-gamma by interleukin-2 analogs.

Heaton KM and 2 others. Ann Surg Oncol, 1994. Cited by 11 papers, by iCite.

Cite this record

ConductScience Library. Induction of lymphokine-activated killing with reduced secretion of interleukin-1 beta, tumor necrosis factor-alpha, and interferon-gamma by interleukin-2 analogs. Papers, record 7842289. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7842289

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Induction of lymphokine-activated killing with reduced secretion of interleukin-1 beta, tumor necrosis factor-alpha, and interferon-gamma by interleukin-2 analogs.
PubMed
Journal
Ann Surg Oncol
PubMed
Year
1994
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
11
iCite
Relative citation ratio, by iCite
0.2
iCite
Revised in PubMed
2019-09-20
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Heaton KMK M
2Ju GG
3Grimm EAE A

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cytotoxicity, ImmunologicMajor topic
Interferon-gammaMajor topic
Interleukin-1Major topic
Interleukin-2Major topic
Killer Cells, Lymphokine-ActivatedMajor topic
Tumor Necrosis Factor-alphaMajor topic
Cytotoxicity Tests, Immunologic
Humans
Immunotherapy, Adoptive
Leukocytes, Mononuclear
Neoplasms
Recombinant Proteins

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
5 T32 CA09500-04NCI NIH HHSUnited StatesT32CA095000PubMedNIH RePORTER
CA45445NCI NIH HHSUnited StatesPubMedPubMed

Download CSV of grants

References31

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
11760811Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity.Cancer Immunol Immunother1991https://conductscience.org/library/papers/1760811PubMed
22052547Localization in human interleukin 2 of the binding site to the alpha chain (p55) of the interleukin 2 receptor.Proc Natl Acad Sci U S A1991https://conductscience.org/library/papers/2052547PubMed
32679456Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.Ann Surg1989https://conductscience.org/library/papers/2679456PubMed
46403654Ia expression by vascular endothelium is inducible by activated T cells and by human gamma interferon.J Exp Med1983https://conductscience.org/library/papers/6403654PubMed
52066765Interleukin-2 toxicity.J Clin Oncol1991https://conductscience.org/library/papers/2066765PubMed
63495302Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients.Blood1987https://conductscience.org/library/papers/3495302PubMed
71858030Pentoxifylline inhibits interleukin-2-induced leukocyte-endothelial adherence and reduces systemic toxicity.Surgery1991https://conductscience.org/library/papers/1858030PubMed
81356627Interferon gamma but not tumor necrosis factor alpha decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells.Cancer Immunol Immunother1992https://conductscience.org/library/papers/1356627PubMed
92647913A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.J Clin Oncol1989https://conductscience.org/library/papers/2647913PubMed
103134297IL-1 and IFN-gamma increase vascular permeability.Immunology1988https://conductscience.org/library/papers/3134297PubMed
113258319Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.J Clin Invest1988https://conductscience.org/library/papers/3258319PubMed
123493433Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.N Engl J Med1987https://conductscience.org/library/papers/3493433PubMed
131596901Interleukin 2 acutely induces platelet and neutrophil-endothelial adherence and macromolecular leakage.Cancer Res1992https://conductscience.org/library/papers/1596901PubMed
146176669Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.J Exp Med1982https://conductscience.org/library/papers/6176669PubMed
151515427Reversible cardiomyopathy after high-dose interleukin-2 therapy.J Immunother (1991)1992https://conductscience.org/library/papers/1515427PubMed
163258039Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice.J Natl Cancer Inst1988https://conductscience.org/library/papers/3258039PubMed
172788701Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity.J Exp Med1989https://conductscience.org/library/papers/2788701PubMed
183123071Functional differentiation of human lymphokine-activated killing (LAK) is distinct from expansion and involves dissimilar interleukin 2 receptors.Cell Immunol1988https://conductscience.org/library/papers/3123071PubMed
191375656Increased circulating nitrogen oxides after human tumor immunotherapy: correlation with toxic hemodynamic changes.J Natl Cancer Inst1992https://conductscience.org/library/papers/1375656PubMed
203129500Characteristics and mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells.J Immunol1988https://conductscience.org/library/papers/3129500PubMed

See all 31 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.

PMIDTitleJournalYearIn PapersSource
40201389Cytokine Couture: Designer IL2 Molecules for the Treatment of Disease.Immunotargets Ther2025https://conductscience.org/library/papers/40201389PubMed
37815596Immunotherapies landscape and associated inhibitors for the treatment of cervical cancer.Med Oncol2023https://conductscience.org/library/papers/37815596PubMed
35213635Human IL-2Rɑ subunit binding modulation of IL-2 through a decline in electrostatic interactions: A computational and experimental approach.PLoS One2022https://conductscience.org/library/papers/35213635PubMed
34553029Prognostic and therapeutic TILs of cervical cancer-Current advances and future perspectives.Mol Ther Oncolytics2021https://conductscience.org/library/papers/34553029PubMed

Download CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
IFNG3458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene
IL1B3553PubTator's text mininghttps://conductscience.org/library/genes/3553NCBI Gene
IL23558PubTator's text mininghttps://conductscience.org/library/genes/3558NCBI Gene
IL2RB3560PubTator's text mininghttps://conductscience.org/library/genes/3560NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/7842289

GET https://conductscience.org/api/papers/v1/7842289/references?page=2